Metabolic disorder therapeutic - Kaleido Biosciences

Drug Profile

Metabolic disorder therapeutic - Kaleido Biosciences

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaleido Biosciences
  • Class Polysaccharides
  • Mechanism of Action Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Metabolic disorders

Most Recent Events

  • 25 Sep 2017 Kaleido Biosciences has patents pending for microbiome-targeted therapeutics globally and in Europe, Australia, USA
  • 18 Sep 2017 Clinical trials in Metabolic disorders (unspecified route) before September 2017 (Kaleido Biosciences pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top